PCVX vs PVLA Stock Comparison
PVLA currently leads PCVX in this stock comparison, with AIQ scores of 70 vs 66. The clearest difference is quality, while PCVX has the stronger risk resilience profile.
What is the main difference between PCVX and PVLA?
PVLA leads the current stock comparison as Palvella Therapeutics, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Vaxcyte, Inc. vs Palvella Therapeutics, Inc.
PVLA leads
PVLA leads by 4 AIQ points, primarily on Quality, having only recently taken the lead back from PCVX. Wall Street currently favors PCVX on target upside.
Fragile: 2 of 5 evidence groups support PVLA, the lead recently changed hands, and its signal state is cleanly positive.
Vaxcyte, Inc.
Palvella Therapeutics, Inc.
The Algovestiq AIQ Score currently favors PVLA over PCVX, 70 versus 66 as of Nov 15, 2026. PVLA's advantage is driven primarily by stronger quality, while PCVX holds the stronger risk resilience profile. PVLA also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors PCVX. 2 of 5 covered evidence groups favor PVLA today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 4 points. PVLA lead: Reversed — PCVX led by 6 AIQ points 30 sessions ago; PVLA now leads by 4.
Compare Vaxcyte, Inc. and Palvella Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare PCVX and PVLA against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality54 vs 65PVLA +11
- Risk Resilience53 vs 47PCVX +6
- Momentum81 vs 84Even
2 of 5 evidence groups favor PVLA. PVLA’s edge is concentrated in quality; PCVX keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1, not enough on its own to move the overall score.
New signals
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-18.8%)
- RSI Midline Rejection — bearish, momentum, short horizon
Largest factor move: Momentum +4
No signal started or stopped since the prior session; its 5 active signals are unchanged.
PVLA's lead widened by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — PCVX and PVLA both carry a full feed there.
The central trade-off
PVLA (Palvella Therapeutics, Inc.): the stronger current systematic profile, led by quality.
PCVX (Vaxcyte, Inc.): the counter-case, on risk resilience, fundamentals, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
PVLAPVLA on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
PCVXPCVX on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
EvenThe two are level on Momentum.
Lower downside
PCVXPCVX on Risk Resilience, by 6 points.
Analyst upside
PCVXPCVX on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors PVLA, analyst targets favor PCVX. That disagreement is the most useful thing on this page.
| Measure | PCVX | PVLA | Note |
|---|---|---|---|
| Implied upside to target | +93% | +55.6% | PCVX has more room |
| Target dispersion | +4.1% | +8.4% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 11 | 16 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 5 covered evidence groups favor PVLA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | PVLA | 66 vs 70 |
| Fundamentals | PCVX | revenue growth 0% vs 0%; EPS growth -1% vs -11.8%; TTM ROE -11.9% vs -12.5%; gross margin 0% vs 0%; operating margin 0% vs 0% |
| Valuation | Not covered | Not covered |
| Technicals | PVLA | Price vs 50-day 1.8% vs 6.2%; vs 200-day 9.8% vs 16.9% |
| Risk Resilience | PCVX | Risk Resilience 53 vs 47 |
| Analyst expectations | PCVX | Target upside 93% vs 55.6% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of PCVX and PVLA and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 4 points. (argues the conclusion is provisional)
- Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on PVLA.
How the comparison changed
120 daily snapshots · May 27 – Nov 13PVLA lead: Reversed — PCVX led by 6 AIQ points 30 sessions ago; PVLA now leads by 4.
- Today
- PVLA +4
- 66 vs 70
- 7 sessions ago
- PVLA +1
- 66 vs 67
- 30 sessions ago
- PCVX +6
- 67 vs 61
- 90 sessions ago
- PVLA +8
- 63 vs 71
The lead changed hands once in this window, most recently on Nov 4 when PVLA moved ahead of PCVX.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
5 bullish / 2 bearish / 1 neutral, conflicted
Only PCVX
- Beta Spike Warning — bearish, risk_regime, long horizon
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-18.8%)
- RSI Midline Rejection — bearish, momentum, short horizon
4 bullish / 0 bearish / 1 neutral
No signal that the other name lacks.
Both carry 5 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish, TRIX Bullish Signal, Uptrend Structure Active.
PCVX is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -2.04%, AIQ 0 points).
Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -0.46%, AIQ +2 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1PCVX closes the Quality gap — currently 11 points behind, the largest single contributor to PVLA's edge.
- 2PCVX's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3PVLA's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
PCVX leads on balance| Metric | PCVX | PVLA |
|---|---|---|
| Revenue growth (YoY) | 0% | 0% |
| EPS growth (YoY) | -1% | -11.8% |
| Gross margin | 0% | 0% |
| Operating margin | 0% | 0% |
| Return on equity (TTM) | -11.9% | -12.5% |
| Debt to equity | 0.09 | 0 |
Performance
PVLA leads 4 of 6 windows| Metric | PCVX | PVLA |
|---|---|---|
| 1 week (5 sessions) | -0.8% | -13.3% |
| 1 month (20 sessions) | -0.4% | 26.7% |
| 3 months (63 sessions) | 5.2% | -0.7% |
| 6 months (126 sessions) | 21% | 33.5% |
| Year to date | 37.3% | 45.7% |
| 1 year (252 sessions) | 37.5% | 87% |
Technicals
PVLA has the stronger structure| Metric | PCVX | PVLA |
|---|---|---|
| RSI (14) | 49.5 | 52.6 |
| ADX (14) | 26.6 | 31.1 |
| Price vs 50-day | 1.8% | 6.2% |
| Price vs 200-day | 9.8% | 16.9% |
| Volatility (1M, annualized) | 58.3% | 75.1% |
Risk
PCVX is the more resilient| Metric | PCVX | PVLA |
|---|---|---|
| Beta | 1.26 | 1.65 |
| Sharpe ratio | 0.79 | 1.12 |
| Sortino ratio | 1.39 | 1.87 |
| Max drawdown | -28% | -31.1% |
| Current drawdown | -14.2% | -13.3% |
| Annualized volatility | 56.2% | 84.5% |
| Value at risk (95%) | -4.1% | -6.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, PCVX or PVLA?
On the Algovestiq AIQ Score, PVLA is the stronger of the two as of Nov 15, 2026, scoring 70 against PCVX's 66. The edge comes from quality. PCVX is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is PCVX or PVLA the better buy right now?
PVLA carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 4 points. Treat the lead as provisional.
Why does the AIQ Score favor PVLA over PCVX?
The composite weights Quality, Value, Momentum and Risk Resilience. PVLA leads Quality by 11 points; PCVX leads Risk Resilience by 6 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, PCVX or PVLA?
Analyst price targets imply +93% upside for PCVX and +55.6% for PVLA, so the Street currently favors PCVX. That points the opposite way to the AIQ Score, which favors PVLA. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, PCVX or PVLA?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, PCVX or PVLA?
PCVX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, PCVX or PVLA?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, PCVX or PVLA?
PCVX is the more resilient of the two, so the other name carries the higher downside risk. PCVX on Risk Resilience, by 6 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is PCVX more profitable than PVLA?
PCVX leads on the comparable margin measures — gross margin 0% vs 0%; operating margin 0% vs 0%; ttm roe -11.9% vs -12.5%.
Is PVLA's lead over PCVX getting stronger or weaker?
PVLA lead: Reversed — PCVX led by 6 AIQ points 30 sessions ago; PVLA now leads by 4. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-11-04, when PVLA moved ahead of PCVX.
What would change the PCVX vs PVLA verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PCVX closes the Quality gap — currently 11 points behind, the largest single contributor to PVLA's edge; PCVX's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; PVLA's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about PCVX and PVLA?
PCVX: 5 bullish / 2 bearish / 1 neutral, conflicted. PVLA: 4 bullish / 0 bearish / 1 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on PCVX is Golden Cross Active (bullish, long horizon). On PVLA it is Golden Cross Active (bullish, long horizon).
Compare PCVX and PVLA with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.